Table 4.
Percentage of individuals with mg/kg doses below or above the therapeutic dose range (according to [30]) of 2–10 mg/kg dihydroartemisinin (DHA) and 16–26 mg/kg piperaquine (PPQ) in each weight- and age-based dosing band
|
Number of tablets |
|
Age-based dosing regimen |
Weight-based dosing regimen |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Global | Africa | Asia | Latin America | Global | Africa | Asia | Latin America | ||
| 0.5 × 20/160 mg |
n |
1037 |
657 |
1037 |
657 |
99 |
89 |
105 |
35 |
| |
DHA below |
99.04% |
98.48% |
99.04% |
99.85% |
100.00% |
100.00% |
100.00% |
100.00% |
| |
DHA above |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| |
PPQ below |
99.04% |
98.48% |
99.04% |
99.85% |
100.00% |
100.00% |
100.00% |
100.00% |
| |
PPQ above |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| 1 × 20/160 mg |
n |
2836 |
2825 |
3222 |
2037 |
1343 |
1204 |
1401 |
1003 |
| |
DHA below |
98.55% |
95.72% |
98.70% |
98.63% |
59.20% |
57.97% |
59.31% |
61.32% |
| |
DHA above |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| |
PPQ below |
98.55% |
95.72% |
98.70% |
98.63% |
59.20% |
57.97% |
59.31% |
61.32% |
| |
PPQ above |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| 1 × 40/320 mg |
n |
2005 |
2396 |
2053 |
1973 |
2946 |
2499 |
3063 |
2106 |
| |
DHA below |
87.23% |
94.49% |
93.18% |
93.82% |
29.33% |
32.53% |
28.73% |
31.43% |
| |
DHA above |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| |
PPQ below |
87.23% |
94.49% |
93.18% |
93.82% |
29.33% |
32.53% |
28.73% |
31.43% |
| |
PPQ above |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| 2 × 40/320 mg |
n |
4122 |
2104 |
3688 |
2054 |
1908 |
1606 |
1990 |
1462 |
| |
DHA below |
64.07% |
86.98% |
60.93% |
77.07% |
0.00% |
0.00% |
0.00% |
0.00% |
| |
DHA above |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| |
PPQ below |
64.07% |
86.98% |
60.93% |
77.07% |
0.00% |
0.00% |
0.00% |
0.00% |
| |
PPQ above |
0.05% |
0.00% |
0.00% |
0.15% |
5.56% |
6.79% |
5.48% |
5.54% |
| 3 × 40/320 mg |
n |
0 |
2018 |
0 |
3279 |
3686 |
4491 |
3441 |
5174 |
| |
DHA below |
– |
31.27% |
– |
39.92% |
6.27% |
16.90% |
1.08% |
24.70% |
| |
DHA above |
– |
0.00% |
– |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| |
PPQ below |
– |
31.27% |
– |
39.92% |
6.27% |
16.90% |
1.08% |
24.70% |
| |
PPQ above |
– |
0.05% |
– |
0.00% |
5.18% |
2.58% |
6.02% |
2.11% |
| 4 × 40/320 mg |
n |
0 |
0 |
0 |
0 |
18 |
111 |
0 |
220 |
| |
DHA below |
– |
– |
– |
– |
0.00% |
48.65% |
– |
45.00% |
| |
DHA above |
– |
– |
– |
– |
0.00% |
0.00% |
– |
0.00% |
| |
PPQ below |
– |
– |
– |
– |
0.00% |
48.65% |
– |
45.00% |
| PPQ above | – | – | – | – | 0.00% | 0.00% | – | 0.00% | |
n: number of individuals in respective dosing band.